Rituximab
Rituximab was the first antibody ever approved for cancer (1997). It made chemoimmunotherapy the CLL standard for a decade, and biosimilars keep it cheap and everywhere.
Approved in follicular lymphoma (1997), DLBCL (2006, R-CHOP), CLL (2010, with fludarabine-cyclophosphamide: FCR, the first regimen to show OS benefit in CLL). Superseded in CLL by targeted agents (CLL13, CLL14, ELEVATE-TN) but still used with venetoclax in relapse (MURANO: venetoclax-rituximab 24 months) and in resource-limited settings. Biosimilars (Truxima, Ruxience, Riabni) since 2018.
1.Binds CD20 and clusters it into lipid rafts
- Route
- IV or subcutaneous (Rituxan Hycela)
- Schedule
- CLL: 375 mg/m² cycle 1 then 500 mg/m² cycles 2-6 with chemotherapy or venetoclax
- Monitoring
- Infusion reactions, HBV reactivation (boxed), PML (boxed), late-onset neutropenia
Source: US prescribing information (DailyMed). Doses are for orientation; the current label governs.
- Medicare
- Part B (clinician-administered)
Given by infusion or injection in a clinic or hospital outpatient department, so it is a Part B drug: Medicare pays 80% after the Part B deductible and the patient owes 20% coinsurance, uncapped in Original Medicare unless a Medigap policy applies. HCPCS J9312 for Rituxan; biosimilars Truxima, Ruxience and Riabni have their own codes. Rituxan Hycela (subcutaneous) is Part B.
- Commercial insurance
- step therapy common
Preferred rituximab biosimilar required by most commercial medical-benefit programmes; prior authorisation confirms CD20-positive disease.
- Assistance programmes
- Genentech Access Solutions
- Genentech Patient Foundation — Free medicine for eligible patients regardless of insurance type.
- PAN Foundation — Disease-specific co-pay and premium funds; open and closed funds change monthly.
- HealthWell Foundation
- CancerCare Co-Payment Assistance Foundation
- Patient Advocate Foundation Co-Pay Relief
- Leukemia & Lymphoma Society financial support
20% Part B coinsurance on a high-cost infusion adds up quickly: Medigap Plan G or N, Medicare Advantage maximum out-of-pocket, Medicaid dual eligibility, or a charity fund are the usual buffers.
Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B) · FDA: Biosimilars. Not medical or financial advice; verify with your plan.
- Appraised for
- Aggressive (diffuse large B-cell) non-Hodgkin lymphoma with CHOP
- Notes
- Follicular lymphoma (TA110, TA137, TA226), CLL (TA174, TA193). Biosimilars since 2017 dominate NHS use. Subcutaneous form available.
- NHS England
- Routinely funded for the appraised indication (or via managed access)
Sources: NICE TA65 · SMC advice: rituximab. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 1997 | Relapsed follicular lymphoma; first antibody approved for cancer |
| US | 2010 | CLL with fludarabine and cyclophosphamide |
| Adverse event | Any grade | Grade 3+ |
|---|---|---|
| Infusion-related reactions (first infusion) Historic lymphoma data; lower with premedication | 77% | — |
| Hepatitis B reactivation Boxed warning; screen all patients | — | — |
| Late-onset neutropenia | 8% | — |
Rates read from the US prescribing information. Blank cells mean the figure was not sourced, not that it is zero.
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
POLARIX gave the first new first-line standard for DLBCL since rituximab was added to CHOP, and pola-R-CHP is now approved and widely used, especially in higher-risk or ABC-type disease. The gain is modest and survival is unchanged, so many clinicians still use R-CHOP in lower-risk or GCB-type patients. Cost and subgroup uncertainty drive ongoing debate.
MURANO made fixed-duration venetoclax the standard for relapsed CLL and showed that stopping therapy after a deep response is safe for most patients. It also established MRD at end of treatment as a practical guide to who is likely to stay in remission. Retreatment with venetoclax at relapse appears feasible.
Latest papers
topQuery for this drug: (TITLE:"Rituximab" OR ABSTRACT:"Rituximab" OR TITLE:"Rituxan" OR ABSTRACT:"Rituxan" OR TITLE:"MabThera" OR ABSTRACT:"MabThera" OR TITLE:"and biosimilars" OR ABSTRACT:"and biosimilars") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Rituximab, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductObinutuzumab
Shares CLL13 / GAIA, ADCC (antibody-dependent cellular cytotoxicity), Complement in cancer, NK-cell recognition: missing self & stress ligands.
- ProductBendamustine
Shares R-CHOP (lymphoma chemoimmunotherapy), MURANO: two years of venetoclax plus rituximab versus chemo-immunotherapy in relapsed CLL, Waldenström macroglobulinaemia, Mantle cell lymphoma.
- Termdel(17p) / TP53 aberration in CLL
Shares Caution: chemoimmunotherapy in del(17p)/TP53 CLL, SEQUOIA, MURANO: two years of venetoclax plus rituximab versus chemo-immunotherapy in relapsed CLL, Mantle cell lymphoma.
- ProductZanubrutinib
Shares Caution: chemoimmunotherapy in del(17p)/TP53 CLL, SEQUOIA, Waldenström macroglobulinaemia, Mantle cell lymphoma.
- CollectionLymphoma Research Foundation (LRF)
Shares Primary CNS lymphoma, Waldenström macroglobulinaemia, Mantle cell lymphoma, Follicular lymphoma.
- TargetCD79b
Shares POLARIX: swapping vincristine for the antibody-drug conjugate polatuzumab vedotin in first-line treatment of diffuse large B-cell lymphoma, Primary CNS lymphoma, Mantle cell lymphoma, Follicular lymphoma.
- TargetBTK (Bruton tyrosine kinase)
Shares SEQUOIA, CLL13 / GAIA, Hairy cell leukaemia, Primary CNS lymphoma.
- CompanyAbbVie (incl. ImmunoGen, Capstan)
Shares MURANO: two years of venetoclax plus rituximab versus chemo-immunotherapy in relapsed CLL, Primary CNS lymphoma, Waldenström macroglobulinaemia, Mantle cell lymphoma.